Back to UBS Group AG UBS Group AG

INMINM
7 quarters

Position history for UBS Group AGUBS Group AG's holdings in INMED PHARMACEUTICALS INC

No. Ubs exited its INM (Inmed Pharmaceuticals) position in Q2 2026. Its Q1 2026 13F listed 8,068 shares worth $5,204. Ubs first reported INM in Q4 2024 and held it in 5 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$49,334

Total Shares Change

-10,408

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$1.55
0
2026-Q1
Increased
8,068
+2040.0%
$5,2040.0%$0.76
17
2025-Q4
New
377
-
$4000.0%$1.10
17
2025-Q3
Exited
0
-100.0%
$00.0%$2.27
0
2025-Q2
Increased
7,762
+27.1%
$25,2270.0%$3.38
16
2025-Q1
Decreased
6,106
-41.3%
$12,6390.0%$2.06
0
2024-Q4
New
10,408
-
$49,3340.0%$4.59
31

Other major holders of INM: JANE STREET GROUP, LLC, Virtu Financial LLC, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used